TRVI — Trevi Therapeutics, Inc.
Is TRVI overbought or oversold? Here is the current MarketMoodz read.
Trevi Therapeutics, Inc. (TRVI) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $13.51. The rating moved from Oversold to Strong Oversold on November 16, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$13.51
- Last changeMoved from Oversold to Strong Oversold on November 16, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Trevi Therapeutics, Inc. (TRVI) appears to be a small, clinical-stage healthcare name where valuation is driven primarily by pipeline milestones, cash runway visibility, and newsflow. There is limited public financial detail in the supplied materials, which elevates uncertainty around near-term funding needs and dilution risk. Near-term upside would likely depend on positive clinical data, licensing/partnership announcements, or acquisition interest from larger pharma consolidators; downside would be driven by trial setbacks, capital raises, or weak market liquidity. Macro and sector flows currently favor large-cap defensive pharma, reducing speculative capital for smaller biotechs absent clear catalysts. Overall scenarios range from binary upside in the event of clinical or corporate catalysts to material downside if financing or clinical risks materialize.
Key factors
- Clinical-stage / pipeline exposure drives binary upside from trial readouts or partnering opportunities
- Limited public financial disclosure available in the provided data (no EDGAR comparison), producing uncertainty on cash runway and burn
- Small-cap liquidity and volatility profile makes shares sensitive to newsflow and sector rotation
- Defensive flows into large-cap pharma reduce risk appetite for small biotech, but acquisitive large pharma trend can create takeover optionality
- Absence of strong social sentiment or research coverage increases reliance on catalysts rather than retail momentum
- Macro/market environment showing consolidation, which favors names with clear near-term catalysts or strong balance sheets
Risks
- Clinical or regulatory setbacks for lead programs could materially reduce valuation
- Insufficient cash runway or need to raise capital leading to dilution at unfavorable terms
- Low trading liquidity driving outsized intraday moves and making position exits costly
- Competition from larger, better-capitalized biopharma companies or alternative therapies
- Adverse changes to reimbursement or payer scrutiny that affect commercial prospects for future products
- Lack of timely public disclosures or analyst coverage increasing information asymmetry for investors
See today's live rating, score and targets
Members see the live hourly rating for TRVI — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.